Expert analysis of pharmaceutical brand strategy, biotech naming, oncology market dynamics, and the evolving premium domain landscape for the global life sciences industry.
From oncology to gene therapy, the word "prime" has conquered the scientific and commercial language of pharmaceutical leadership.
The naming decisions made in stealth mode determine brand outcomes for decades. Here is the strategy behind the best biotech names.
A systematic look at the financial return generated by premium brand name investment in the pharmaceutical industry.
In the world's most competitive drug class, brand architecture determines how payers, physicians, and patients engage with your therapy.
As gene therapy enters the commercial mainstream, the brands that lead will be those that speak the language of scientific precision and clinical authority.
The rare disease sector's most successful brands share a naming pattern — and it has nothing to do with describing what the drug does.
Primedita.com available for acquisition now.